TSPO-specific ligand Vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation

Neuron Glia Biology

Volumn 7, Issue 2-4, 2011, Pages 187-197

  Zhao, Yan Yin ^a,b   Yu, Jie Zhong ^c   Li, Qin Ying ^a,b   Ma, Cun Gen ^c   Lu, Chuan Zhen ^a,b   Xiao, Bao Guo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANXI DATONG UNIVERSITY   (China)

Author keywords

Anti inflammation; Microglia; Translocator protein; Vinpocetine

Indexed keywords

BETA ACTIN; CARRIER PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; HYPOXIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL DEATH; CELL LINE, TRANSFORMED; CELLS, CULTURED; CEREBRAL CORTEX; DOWN-REGULATION; INFLAMMATION; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROPROTECTIVE AGENTS; RECEPTORS, GABA; UP-REGULATION; VINCA ALKALOIDS;

MUS;

EID: 84871318150     PISSN: 1740925X     EISSN: 17410533     Source Type: Journal    
DOI: 10.1017/S1740925X12000129     Document Type: Article

References (32)

1. Adám-Vizi V. (2000) Neuroprotective effect of sodium channel blockers in ischemia: the pathomechanism of early ischemic dysfunction. Orvosi Hetilap 141, 1279-1286.
2. Amor S., Puentes F., Baker D. and van der Valk P. (2010) Inflammation in neurodegenerative diseases. Immunology 129, 154-169.
3. Bagoly E., Fehér G. and Szapáry L. (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orvosi Hetilap 148, 1353-1358.
4. Banati R.B. (2002) Visualisingmicroglial activation in vivo. Glia 40, 206-217.
5. Bocchini V., Mazzolla R., Barluzzi R., Blasi E., Sick P. and Kettenmann H. (1992) An immortalized cell line expresses properties of activated microglial cells. Journal of Neuroscience Research 31, 616-621.
6. Bönöczk P., Gulyás B., Adam-Vizi V., Nemes A., Kárpáti E., Kiss B. et al. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Research Bulletin 53, 245-254.
7. Ceulemans A.G., Zgavc T., Kooijman R., Hachimi-Idrissi S., Sarre S. and Michotte Y. (2010) The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. Journal of Neuroinflammation 7, 74.
8. Chen M.K. and Guilarte T.R. (2008) Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacology and Therapeutics 118, 1-17.
9. Emmanouil M., Taoufik E., Tseveleki V., Vamvakas S.S. and Probert L. (2011) A role for neuronal NF-kB in suppressing neuroinflammation and promoting neuroprotection in the CNS. Advances in Experimental Medicine and Biology 691, 575-581.
10. Feigin V.L., Doronin B.M., Popova T.F., Gribatcheva E.V. and Tchervov D.V. (2001) Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. European Journal of Neurology 8, 81-85.
11. Galimberti D. and Scarpini E. (2011) Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Frontiers in Bioscience 3, 252-266.
12. Giachini F.R., Lima V.V., Carneiro F.S., Tostes R.C. and Webb R.C. (2011) Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension 57, 655-663.
13. Gulyas B., Halldin C., Vas A., Banati R.B., Shchukin E. and Finnema S. et al. (2005) [11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. Journal of Neurological Sciences 229-230, 219-223.
14. Gulyas B., Toth M., Vas A., Shchukin E., Kostulas K and Hillert J. et al. (2012) Halldin C. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. Current Radiopharmaceuticals 5, 19-28.
15. Hall H., Varnäs K., Sandell J., Halldin C., Farde L. and Vas A. et al. (2002) Autoradiographic evaluation of [11C]vinpocetine binding in the human postmortem brain. Acta Biologica Hungarica 53, 59-66.
16. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H. and Kwon D.S. et al. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proceedings of the National Academy of Sciences of the U.S.A. 107, 9795-9800.
17. Lue L.F., Kuo Y.M., Beach T. and Walker D.G. (2010) Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Molecular Neurobiology 41, 115-128.
18. Medina A.E. (2010) Vinpocetine as a potent antiinflammatory agent. Proceedings of the National Academy of Sciences of the U.S.A. 107, 9921-9922.
19. Myers R., Manjil L.G., Cullen B.M., Price G.W., Frackowiak R.S. and Cremer J.E. (1991) Macrophage and astrocyte populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion. Journal of Cerebral Blood Flow and Metabolism 11, 314-322.
20. Okamoto H. (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. New England Journal of Medicine 355, 2047.
21. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J.J. and Lindemann P. et al. (2006) Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends in Pharmacological Sciences 27, 402-409.
22. Papadopoulos V. and Lecanu L. (2009) Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Experimental Neurology 219, 53-57.
23. Perry V.H., Nicoll J.A. and Holmes C. (2010) Microglia in neurodegenerative disease. Nature Reviews. Neurology 6, 193-201.
24. Rivest S. (2011) The promise of anti-inflammatory therapies for CNS injuries and siseases. Expert Review of Neurotherapeutics 11, 783-786.
25. Rossi B., Angiari S., Zenaro E., Budui S.L. and Constantin G. (2011) Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. Journal of Leukocyte Biology 89, 539-556.
26. Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J. and Akula N. et al. (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews. Drug Discovery 9, 971-988.
27. Shimizu K., Murata T., Watanabe Y., Sato C., Morita H. and Tagawa T. (2009) Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Research 29, 1119-1122.
28. Stephenson D.T., Schober D.A., Smalstig E.B., Mincy R.E., Gehlert D.R. and Clemens J.A. (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. Journal of Neuroscience 15, 5263-5274.
29. Szobor A. and Klein M. (1976) Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 26, 1984-1989.
30. Tamaki N. and Matsumoto S. (1985) Agents to improve cerebrovascular circulation and cerebral metabolism - vinpocetine. Nippon Rinsho 43, 376-378.
31. Walter L. and Neumann H. (2009) Role of microglia in neuronal degeneration and regeneration. Seminars in Immunopathology 31, 513-525.
32. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E. and Greenberg N. (2006) Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nature Neuroscience 9, 268-275.